Ludwig Enterprises Inc (OTCMKTS:LUDG) Stock Gains Momentum: Here is Why

On Tuesday, Ludwig Enterprises Inc (OTCMKTS:LUDG) was in the news after it announced that the bladder cancer study that it had been conducting along with its subsidiary unit Precision Genomics Inc had been approved by the Institutional Review Board.

Ludwig Enterprises Receives IRB Approval on Bladder Cancer Study

The study in question is titled “Using Measurements of mRNA and Elisa-based Cytokine/Protein Indices to Evaluate Pre- and Post- Diagnosis and Treatment Response of Patients WithUrothelial Carcinoma of the Bladder.” It was a major new development for the company and it now remains to be seen if the Ludwig Enterprises stock comes into focus among investors over the coming days or not.

The chairman of the company’s Scientific Advisory Board Dr Marvin S Hausman spoke about the latest development as well. He noted that the study was ground breaking and had the potential of revolutionising cancer detection as well as treatment.

That would be made possible through the development of a predictive model which could detect cancer at an early stage. In this situation, it may be a good move for investors to consider keeping an eye on the progress that is made by Ludwig in the coming months. The stock may be tracked as well.

Key Quote

Dr. Marvin S. Hausman, MD, Chairman of Ludwig’s Scientific Advisory Board (SAB), stated, “this ground-breaking research study has the potential to transform cancer detection and treatment by producing a predictive model for early-stage cancer occurrences. The proprietary genomic language developed could change medical care by capturing an individual snapshot of disease progression in combination with a patient’s response to certain treatments-enabling doctors to better serve their patients’ needs proactively rather than reactively. Ludwig intends to make this research program available to Urology doctors and clinics throughout the United States.”